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Anxiety disorders represent some of the most common mental disorders. The lifetime prevalence rates for the different disor-
ders are between 1% and 13%. Most anxiety disorders have a chronic, waxing and waning course. The impairment patients 
suffer due to the anxiety disorders ranges from mild to incapacitating. It is important that general practitioners understand the 
diagnostic and treatment concepts of the anxiety disorders to ensure early diagnosis and intervention in order to prevent undue 
suffering and impairment.
Introduction
According to the DSM-IV-TR (Diagnostic 
and Statistical Manual – 2000 version) 
anxiety is the apprehensive anticipation 
of a future danger or misfortune that is 
accompanied by a feeling of dyspho-
ria or somatic symptoms of tension.1 
Anxiety is a normal phenomenon. When 
anxiety is accompanied by undue sub-
jective distress or causes impairment of 
general functioning, a mental disorder 
may be present. This paper deals with 
anxiety disorders in adults.
Anxiety disorders represent some of 
the most common mental disorders. The 
lifetime prevalence rates for the different 
disorders are between 1% and 13%.1 
Most anxiety disorders have a chronic, 
waxing and waning course. The impair-
ment patients suffer due to the anxiety 
disorders ranges from mild to inca-
pacitating.1 It is important that general 
practitioners understand the diagnostic 
and treatment concepts of the anxiety 
disorders to ensure early diagnosis and 
intervention in order to prevent undue 
suffering and impairment.
Understanding the diagnostic con-
cepts as defined by the DSM-IV-TR or 
ICD-10 (International Classification of 
Diseases – latest version) criteria may 
already be daunting, but to complicate 
matters further,  anxiety disorders sel-
dom present in isolation. Furthermore 
anxiety may be the presenting symp-
tom of another psychiatric disorder or 
of a physical illness, for example, the 
presenting complaint of a patient with 
a major depressive disorder may be 
anxiety, and that of hypochondriasis 
may be worry. Hyperthyroidism may 
present with anxiety and so may caf-
feine intoxication.
Often there are comorbid disorders 
like other psychiatric disorders and 
physical illnesses.2 This implies that a 
medical practitioner having detected an 
anxiety disorder should search for the 
presence of other psychiatric disorders 
and physical illnesses. The physical ill-
nesses may be the cause of the anxiety 
or may be completely unrelated to it.
The anxiety disorders
The DSM-IV-TR differentiates between 
twelve anxiety disorders.1 They are listed 
in Table 1. Although it is not an anxiety 
disorder, an Adjustment Disorder With 
Anxiety has been included here for the 
purposes of discussion.
The DSM-IV-TR should be consulted 
for the exact criteria of the different dis-
orders. Here the basic concept behind 
each of the disorders will be introduced. 
If one is familiar with the basic concept 
behind the disorder, one is more likely 
to suspect its presence and to check 
whether the criteria have been met.
The main feature of an Anxiety Disor-
der Due to a General Medical Condition 
is the presence of prominent symptoms 
of anxiety judged to be caused by the 
direct physiological effects of a medical 
condition. Chronic obstructive airways 
disease, for example, can cause anxiety 
that may manifest with panic attacks.
The main feature of a Substance-
Induced Anxiety Disorder is the pres-
ence of prominent symptoms of anxiety 
judged to be caused by the direct 
physiological effects of a drug of abuse, 
a medication, or a toxin. Thyroxin, for 
example, can cause anxiety that may 
manifest with a generalised anxiety or 
panic attacks.
For the other anxiety disorders the 
main features hold true as long as one 
excludes medical conditions or sub-
stances, and sometimes another psy-
chiatric disorder that may better explain 
the symptoms and signs.
A Panic Disorder is characterised by 
recurrent, unexpected panic attacks 
that trouble the patient in some way or 
lead to changes in behaviour. If agora-
phobia occurs it is called Panic Disorder 
With Agoraphobia; if not, Panic Disorder 
Without Agoraphobia. Agoraphobia’s 
main feature in a Panic Disorder context 
is a fear of experiencing panic attacks 
Anxiety Disorder Due to a General Medical Condition
Substance Induced Anxiety Disorder
Panic Disorder Without Agoraphobia
Panic Disorder With Agoraphobia
Agoraphobia Without History of Panic Disorder
Social Anxiety Disorder (Social Phobia)
Specific Phobia
Obsessive-Compulsive Disorder
Post traumatic Stress Disorder
Acute Stress Disorder
Generalised Anxiety Disorder
Anxiety Disorder Not Otherwise Specified
Table 1: Anxiety disorders ¹
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in situations where escape would be 
difficult or where leaving would be 
embarrassing or where help may not 
be available. Such situations are there-
fore avoided or distressfully endured. 
Agoraphobia Without History of Panic 
Disorder does not comprise full-blown 
panic attacks; however, there are still 
panic-like symptoms present (palpita-
tions, sweating, breathing distress, 
etc). The patient fears these panic-like 
symptoms in situations where escape 
would be difficult or where leaving 
would be embarrassing or where help 
usually may not be available. Patients 
usually avoid these situations or endure 
them with great distress. The main fea-
ture of Social Anxiety Disorder (SAD) 
is experiencing distressing anxiety in 
certain social or performance situations. 
Those situations are mostly avoided or 
endured with much distress.
Specific Phobia refers to distressing 
anxiety precipitated by specific objects 
or situations (other than agoraphobic or 
social situations). Those objects or situ-
ations are then avoided by patients or 
endured with much distress.
Obsessive-Compulsive Disorder (OCD) 
is characterised by the presence of ob-
sessions and/or compulsions that are 
distressing, time-consuming or cause 
functional impairment.
Post-traumatic Stress Disorder (PTSD) 
is characterised by having experienced 
an extremely severe stressor, having 
experienced much distress while the 
stressor was present and then having 
recurrent, distressing re-experiences of 
that stressor.  Such patients also have 
avoidance behaviour and a numbing 
of general responsiveness. They also 
suffer symptoms of increased arousal. 
Acute Stress Disorder (ASD) is much 
like PTSD, but a time criterion is includ-
ed: symptoms must start within four 
weeks, last a minimum of two days and 
a maximum of four weeks.
The main features of Generalised 
Anxiety Disorder (GAD) are excessive 
anxiety and concern for at least six 
months accompanied by certain psy-
chological and physical symptoms of 
autonomic arousal.
Anxiety Disorder Not Otherwise Spec-
ified designates distressing or dysfunc-
tional anxiety that does not fit the de-
scription of a known DSM-IV-TR disor-
der.
Adjustment Disorder With Anxiety (ADWA) 
is a self-limiting disorder characterised 
by the presence of excessive anxiety 
that is distressing or that impairs func-
tioning. It develops following an identifi-
able stressor. It should not be better ex-




Known medical illnesses, medication, 
toxins, and substances of abuse caus-
ing anxiety should be investigated as 
appropriate in each instance. Collat-
eral information may help to clear up 
uncertainties. When a functional anxiety 
disorder is present one should still have 
a high index of suspicion for a medical 
illness as primary cause. Baseline labo-
ratory studies such as thyroid functions, 
urea and electrolytes, basic full blood 
count and serum glucose are often in-
dicated. Liver functions and pregnancy 
studies may be indicated in selected 
cases. Prominent cardiac symptoms 
may warrant an electrocardiogram or 
even blood test for heart enzymes. 
An electroencephalogram should be 
considered when prominent symptoms 
of depersonalisation, derealisation or 
changes in consciousness are present.
Psychoeducation
Psychoeducation is an important part 
of the management of any psychiatric 
disorder and anxiety disorders are 
no exception. In some cases psycho-
education may be all that is needed.3 
for example, patients suffering from 
ADWA may be relieved to know the 
reason for their anxiety, and that it is a 
transient condition. Following adequate 
explanation and concrete guidance 
they may be able to carry on without the 
temporary use of anxiolitics. If a general 
practitioner is trained in problem solving 
techniques it may be usefully applied in 
such instances.
Sometimes people suffering from a 
chronic anxiety disorder find it difficult 
to distinguish between normal and 
abnormal anxiety. They misinterpret 
the unavoidable experiencing of nor-
mal anxiety as an exacerbation of their 
disorder. Careful explanation may allay 
their concerns.
Psychoeducation includes inform-
ing patients about the cause, course, 
treatment and prognosis of the disor-
der. Understanding the disorder better 
may help with compliance. Side-effects 
should be explained. It is especially 
important to explain that some patients’ 
anxiety may worsen initially (on antide-
pressants) before it gets better. It is also 
important to explain the delayed onset 
of action.  Sometimes it may take as 
long as three months to experience the 
full benefit of a drug.
Education about medication and 
substances that cause or exacerbate 
anxiety disorders should be given. The 
intention would be to withdraw and stop 
them where possible.
Psychopharmacology
The anxiety disorders for which drug 
therapy has been established by pla-
cebo-controlled trials are listed in Table 
2. They will be discussed first.
 
For all of the anxiety disorders in Table 
2 the selective serotonin re-uptake 
inhibitors (SSRI’s) like citalopram, es-
citalopram, fluoxetine, fluvoxamine, 
venlafaxine and paroxetine are effica-
cious.4 In addition, buspirone is a first-
line drug of choice for GAD. The anxiety 
disorders need SSRI doses equivalent 
to and higher than those for Major De-
pressive Disorder. If a specific drug is 
effective, treatment should be continued 
for at least 6-12 months.  However for 
many patients treatment will prove to be 
life-long since the incidence of relapses 
after stopping medication is high. 
Continued drug treatment significantly 
reduces the risk of relapse, but does not 
guarantee it.
Because it takes weeks for the SSRI’s 
(and buspirone) to have an effect, it may 
be necessary to add a benzodiazepine 
initially when more rapid onset of action 
is required.  The idea is to provide rapid 
relief with the intention of tapering the 
benzodiazepine later on. Examples are 
severe GAD that causes significant dis-
tress, that causes functional impairment, 
or that worsens a medical condition. In 
such cases oxazepam, lorazepam, and 
many other benzodiazepines would 
help. Similarly, for severe Panic Disorder, 
alprazolam and clonazepam are useful. 
The other benzodiazepines do not reli-
ably prevent panic attacks. Rather than 
prescribing the benzodiazepines as 
needed, they should be prescribed in a 
way that prevents anxiety (for example 
once to thrice a day). This helps prevent 
• Panic Disorder Without Agoraphobia
• Panic Disorder With Agoraphobia
• Social Anxiety Disorder (Social   
   Phobia)
• Obsessive-Compulsive Disorder
• Post-traumatic Stress Disorder
• Generalised Anxiety Disorder
Table 2:  Anxiety disorders for which drug 
therapy has been established
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undue reliance on these drugs later on. 
Keep in mind and warn patients that 
using benzodiazepines involves a risk 
of addiction, drowsiness, slowed reac-
tion time, reduced concentration and 
memory problems. 
In the case of Substance Induced 
Anxiety Disorder or Anxiety Disorder 
Due to a General Medical Condition 
the ideal would be to stop the offend-
ing drug or substance and to treat the 
underlying medical condition. However, 
it may not always be possible. In that 
case the approach would be similar to 
the approach to the “functional” Anxiety 
Disorder.
Referral
Referral to a psychiatrist should be 
considered for all patients suffering from 
ASD, PTSD and OCD. These conditions 
are often difficult to treat. Patients suf-
fering from an anxiety disorder due to 
a medical condition, or a substance in-
duced anxiety disorder, should also be 
considered for referral to a psychiatrist. 
All cases that are complicated, atypi-
cal, or that do not respond adequately 
to treatment should be considered for 
referral to a psychiatrist.
Cognitive-behaviour therapy (CBT) 
should be considered for all patients 
who suffer from an anxiety disorder. 
Table 3 lists anxiety disorders where 
CBT has proved to be effective.5 For 
Specifi c Phobia and Agoraphobia With-
out a History of Panic Disorder, CBT is 
the only reliable treatment.  Patients 
should be referred to psychiatrists and 
clinical psychologists who are adept at 
CBT. However, not all patients are in 
favour of CBT, therefore, referral should 
be discussed with them beforehand.
To help patients with the management 
of stressful life conditions an appropriate 
referral to other members of the mental 
health team may be considered (psy-
chiatrist, clinical psychologist, mental 
health occupational therapist or mental 
health social worker). 
Follow-Up
Once a patient has been stabilised on 
drug therapy, CBT, or a combination of 
the two, the general practitioner may be 
in a good position to do the follow-up of 
the patient in a comprehensive primary 
health care setting. 
See CPD Questionnaire, page 43
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It is well known that HIV/AIDS is the sin-
gle largest contributor to South Africa’s 
burden of disease. It is less well appre-
ciated that neuropsychiatric disorders 
comprise the second largest compo-
nent of our national burden of disease.1 
The National Research Foundation has 
provided funding for a Cross-University 
Brain-Behaviour Initiative (CUBBI). This 
is a research initiative that is focused 
on the psychobiology of vulnerability 
and resilience after psychological trau-
ma, but also hopes to obtain addition-
al funding to tackle other brain-behav-
iour areas that are key in the South Af-
rican context, including HIV/AIDS and 
substance abuse.
GSK initiated this newsletter, in asso-
ciation with the CUBBI, as a service to 
the medical community. This highly in-
formative newsletter will provide practi-
tioners with a series of updates on HIV/
AIDS and mental health, written by re-
spected professionals in their individual 
fields of expertise. 
Prof Dan Stein, Professor and Chair of 
the Department of Psychiatry, Univer-
sity of Cape Town and Director, MRC 
Unit on Anxiety and Stress Disorders, 
University of Stellenbosch, is appoint-
ed as editor. 
The newsletter aims to raise awareness 
and highlight the role and gravity of 
mental health in HIV/AIDS patients. The 
first issue will be available at the end of 
June 2007.
Parties interested in receiving or 
contributing to future issues of the 
newsletter are welcome to contact 
Madelein Steyl, CNS Brand Manager, GSK 
South Africa on Tel : +27 (0)11 745 6046 or 
e-mail: madelein.m.steyl@gsk.com. 
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